Compared with placebo, ATH434 demonstrated a statistically significant 48% slowing of clinical progression (based on UMSARS score) at the 50mg dose at week 52. The Food and Drug Administration ...

Alterity’s previous interactions with the FDA indicated that the modified Unified Multiple System Atrophy Rating Scale (UMSARS) Part I scale is considered a clinically meaningful endpoint for MSA.

(0:54) How does one time surgery for scoliosis in children with pediatric spinal muscular atrophy get a maximum benefit without impeding growth? Dr. Ashley E. Webb of the University of Texas ...